XML 42 R30.htm IDEA: XBRL DOCUMENT
v3.8.0.1

License and Collaboration Agreements - Additional Information (Detail) - USD ($) |  |  | 1 Months Ended | 3 Months Ended | 12 Months Ended |  |
--- | --- | --- | --- | --- | --- | --- | ---
Feb. 13, 2018 | Aug. 23, 2017 | Apr. 30, 2018 | Nov. 30, 2017 | Sep. 30, 2017 | Sep. 30, 2016 | Mar. 31, 2016 | Mar. 31, 2018 | Mar. 31, 2017 | Dec. 31, 2010 | Dec. 31, 2015 | Jan. 01, 2018 | Dec. 31, 2017
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognized in period related to performance in prior periods |  |  |  |  |  |  |  | $ 28,000,000 |  |  |  |  |
Potential future additional payments for development milestones |  |  |  |  |  |  |  | 295,500,000 |  |  |  |  |
Deferred revenue, current portion |  |  |  |  |  |  |  | 19,531,000 |  |  |  |  | $ 18,949,000
Deferred revenue, less current portion |  |  |  |  |  |  |  | 12,808,000 |  |  |  |  | 19,021,000
Deferred revenue |  |  |  |  |  |  |  | $ 32,339,000 |  |  |  |  | $ 37,970,000
AstraZeneca-Kirin [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of upfront payment, market access milestone payments, royalties and sales milestone payments |  |  |  |  |  |  | 40.00% |  |  |  |  |  |
Nektar's [Member] | NKTR-358 [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Received upfront and milestone payment |  |  |  |  | $ 150,000,000 |  |  |  |  |  |  |  |
Percentage of sharing in Phase 2 development costs |  | 25.00% |  |  |  |  |  |  |  |  |  |  |
Regulatory milestones payment, description |  |  |  |  |  |  |  | A portion of the development milestones may be reduced by 50% under certain conditions, related to the final formulation of the approved product and the timing of prior approval (if any) of competitive products with a similar mechanism of action, which could reduce these milestone payments by 75% if both conditions occur. |  |  |  |  |
Deferred revenue |  |  |  |  |  |  |  | $ 17,600,000 |  |  |  |  |
NKTR-214 [Member] | Nektar's [Member] | Subsequent Event [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Non-refundable upfront payment received in cash in future period |  |  | $ 1,000,000,000 |  |  |  |  |  |  |  |  |  |
NKTR-214 [Member] | Nektar's [Member] | Subsequent Event [Member] | Maximum [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Maximum total additional cash payments receivable upon achievement of certain development and regulatory milestones |  |  | 1,430,000,000 |  |  |  |  |  |  |  |  |  |
Eligible additional cash payments receivable upon achievement of certain sales milestones |  |  | $ 350,000,000 |  |  |  |  |  |  |  |  |  |
NKTR-214 [Member] | Nektar's [Member] | BMS Collaboration Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Global commercialization profits and losses sharing percentage | 65.00% |  |  |  |  |  |  |  |  |  |  |  |
NKTR-214 [Member] | Nektar's [Member] | BMS Collaboration Agreement [Member] | Opdivo [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of sharing development costs | 32.50% |  |  |  |  |  |  |  |  |  |  |  |
NKTR-214 [Member] | Nektar's [Member] | BMS Collaboration Agreement [Member] | Opdivo and Yervoy [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of sharing development costs | 22.00% |  |  |  |  |  |  |  |  |  |  |  |
Baxalta Incorporated/Shire [Member] | Hemophilia |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Received under right to sublicense agreement |  |  |  | $ 12,000,000 |  |  |  |  |  |  |  |  |
Baxalta Incorporated/Shire [Member] | Hemophilia | European Union [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront and milestone payments received from license agreements |  |  |  |  |  |  |  | 10,000,000 |  |  |  |  |
Baxalta Incorporated/Shire [Member] | Hemophilia | ASC 606 [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue |  |  |  |  |  |  |  | 1,000,000 |  |  |  |  |
Baxalta Incorporated/Shire [Member] | Hemophilia | ASC 606 [Member] | European Union [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Development milestones received |  |  |  |  |  |  |  | 10,000,000 |  |  |  |  |
Bristol-Myers Squibb [Member] | Subsequent Event [Member] | Purchase Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Shares of common stock purchased |  |  | 8,284,600 |  |  |  |  |  |  |  |  |  |
Sale of stock consideration expected to be received in future period |  |  | $ 850,000,000 |  |  |  |  |  |  |  |  |  |
Issued price per share |  |  | $ 102.60 |  |  |  |  |  |  |  |  |  |
Bristol-Myers Squibb [Member] | NKTR-214 [Member] | BMS Collaboration Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Global commercialization profits and losses sharing percentage | 35.00% |  |  |  |  |  |  |  |  |  |  |  |
Bristol-Myers Squibb [Member] | NKTR-214 [Member] | BMS Collaboration Agreement [Member] | Opdivo [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of sharing development costs | 67.50% |  |  |  |  |  |  |  |  |  |  |  |
Bristol-Myers Squibb [Member] | NKTR-214 [Member] | BMS Collaboration Agreement [Member] | Opdivo and Yervoy [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of sharing development costs | 78.00% |  |  |  |  |  |  |  |  |  |  |  |
Bristol-Myers Squibb [Member] | NKTR-214 [Member] | Clinical Trial Agreement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of out-of-pocket costs to be reimbursed by partner |  |  |  |  |  | 50.00% |  |  |  |  |  |  |
Eli Lilly and Company [Member] | NKTR-358 [Member] | ASC 606 [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue |  |  |  |  |  |  |  |  |  |  |  | $ 19,900,000 |
Eli Lilly and Company [Member] | NKTR-358 [Member] | License [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Received upfront and milestone payment |  |  |  |  | 125,900,000 |  |  |  |  |  |  |  |
Eli Lilly and Company [Member] | NKTR-358 [Member] | License [Member] | ASC 606 [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue related to license activities |  |  |  |  | 125,900,000 |  |  |  |  |  |  |  |
Eli Lilly and Company [Member] | NKTR-358 [Member] | Phase 1 Clinical Development [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Received upfront and milestone payment |  |  |  |  | 17,600,000 |  |  |  |  |  |  |  |
Eli Lilly and Company [Member] | NKTR-358 [Member] | Phase 1 Clinical Development [Member] | ASC 606 [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue |  |  |  |  |  |  |  |  |  |  |  | 14,500,000 |
Eli Lilly and Company [Member] | NKTR-358 [Member] | Drug Product Development [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Received upfront and milestone payment |  |  |  |  | $ 6,500,000 |  |  |  |  |  |  |  |
Eli Lilly and Company [Member] | NKTR-358 [Member] | Drug Product Development [Member] | ASC 606 [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue |  |  |  |  |  |  |  |  |  |  |  | $ 5,400,000 |
Eli Lilly and Company [Member] | NKTR-358 [Member] | Maximum [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Potential future additional development and regulatory milestones |  | $ 250,000,000 |  |  |  |  |  |  |  |  |  |  |
Eli Lilly and Company [Member] | Nektar's [Member] | NKTR-358 [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of regulatory milestones payments will be reduced under certain conditions |  | 50.00% |  |  |  |  |  |  |  |  |  |  |
Percentage of regulatory milestones payments will be reduced if conditions occur |  | 75.00% |  |  |  |  |  |  |  |  |  |  |
Eli Lilly and Company [Member] | Nektar's [Member] | NKTR-358 [Member] | Maximum [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of funding phase 3 development costs on an indication by indication basis borne |  | 25.00% |  |  |  |  |  |  |  |  |  |  |
Eli Lilly and Company [Member] | Nektar's [Member] | NKTR-358 [Member] | Minimum [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of funding phase 3 development costs on an indication by indication basis borne |  | 0.00% |  |  |  |  |  |  |  |  |  |  |
Eli Lilly [Member] | NKTR-358 [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Percentage of sharing in Phase 2 development costs |  | 75.00% |  |  |  |  |  |  |  |  |  |  |
Amgen, Inc. [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Received upfront and milestone payment |  |  |  |  |  |  |  |  |  | $ 50,000,000 |  |  |
Amgen, Inc. [Member] | ASC 606 [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue |  |  |  |  |  |  |  | 12,900,000 |  |  |  |  |
AstraZeneca AB [Member] | MOVANTIK and MOVANTIK fixed-dose combination program [Member] | Upfront Payment Arrangement [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Received upfront and milestone payment |  |  |  |  |  |  |  |  |  |  | $ 385,000,000 |  |
AstraZeneca AB [Member] | MOVANTIK Fixed-dose Combination Program [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Potential contingent payments based on development events |  |  |  |  |  |  |  | 75,000,000 |  |  |  |  |
AstraZeneca AB [Member] | AstraZeneca-Kirin [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Received upfront and milestone payment |  |  |  |  |  |  |  |  | $ 3,000,000 |  |  |  |
Deferred revenue |  |  |  |  |  |  |  | 0 |  |  |  |  |
Percentage of upfront payment, market access milestone payments, royalties and sales milestone payments from sublicense agreement retained by our collaboration partner |  |  |  |  |  |  | 60.00% |  |  |  |  |  |
Other [Member] |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred Revenue Arrangement [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |
Potential future additional payments for development milestones |  |  |  |  |  |  |  | 45,500,000 |  |  |  |  |
Deferred revenue |  |  |  |  |  |  |  | $ 800,000 |  |  |  |  |

X
- Definition Collaborative arrangements maximum aggregate additional cash payments receivable upon achievement of development and regulatory milestones. + References No definition available. + Details
Name: | nktr_CollaborativeArrangementsMaximumAggregateAdditionalCashPaymentsReceivableUponAchievementOfDevelopmentAndRegulatoryMilestones
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Eligible additional cash payments receivable upon achievement of certain sales milestones. + References No definition available. + Details
Name: | nktr_EligibleAdditionalCashPaymentsReceivableUponAchievementOfCertainSalesMilestones
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Non-refundable upfront payment received in cash in future period. + References No definition available. + Details
Name: | nktr_NonRefundableUpfrontPaymentToBeReceivedInCashInFuturePeriod
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Payments received under rights to sublicense agreement. + References No definition available. + Details
Name: | nktr_PaymentsReceivedUnderRightsToSublicenseAgreement
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Percentage of development milestones payments, to be received, if conditions occur. + References No definition available. + Details
Name: | nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedIfConditionsOccur
Namespace Prefix: | nktr_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of development milestones payments, to be received under certain conditions. + References No definition available. + Details
Name: | nktr_PercentageOfDevelopmentMilestonesPaymentsToBeReceivedUnderCertainConditions
Namespace Prefix: | nktr_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of funding Phase three development costs on an indication by indication basis borne. + References No definition available. + Details
Name: | nktr_PercentageOfFundingPhaseThreeDevelopmentCostsOnAnIndicationByIndicationBasisBorne
Namespace Prefix: | nktr_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of out of pocket costs to be reimbursed by partner. + References No definition available. + Details
Name: | nktr_PercentageOfOutOfPocketCostsToBeReimbursedByPartner
Namespace Prefix: | nktr_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of sharing in development costs. + References No definition available. + Details
Name: | nktr_PercentageOfSharingInDevelopmentCosts
Namespace Prefix: | nktr_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of sharing in Phase 2 development costs. + References No definition available. + Details
Name: | nktr_PercentageOfSharingInPhaseTwoDevelopmentCosts
Namespace Prefix: | nktr_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of upfront payment, market access milestone payments, royalties and sales milestone payments. + References No definition available. + Details
Name: | nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePayments
Namespace Prefix: | nktr_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of upfront payment market access milestone payments royalties and sales milestone payments from sublicense agreement retained by our collaboration partner. + References No definition available. + Details
Name: | nktr_PercentageOfUpfrontPaymentMarketAccessMilestonePaymentsRoyaltiesAndSalesMilestonePaymentsFromSublicenseAgreementRetainedByOurCollaborationPartner
Namespace Prefix: | nktr_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Potential contingent payments based on development events. + References No definition available. + Details
Name: | nktr_PotentialContingentPaymentsBasedOnDevelopmentEvents
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Potential development and regulatory milestones. + References No definition available. + Details
Name: | nktr_PotentialDevelopmentAndRegulatoryMilestones
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Potential development milestones. + References No definition available. + Details
Name: | nktr_PotentialDevelopmentMilestones
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Profits and losses sharing percentage. + References No definition available. + Details
Name: | nktr_ProfitsAndLossesSharingPercentage
Namespace Prefix: | nktr_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Regulatory milestones payment description. + References No definition available. + Details
Name: | nktr_RegulatoryMilestonesPaymentDescription
Namespace Prefix: | nktr_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Revenue recognized in period related to performance in prior periods. + References No definition available. + Details
Name: | nktr_RevenueRecognizedInPeriodRelatedToPerformanceInPriorPeriods
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Sale of stock consideration expected to be received in future period. + References No definition available. + Details
Name: | nktr_SaleOfStockConsiderationExpectedToBeReceivedInFuturePeriod
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Shares of common stock purchased. + References No definition available. + Details
Name: | nktr_SharesOfCommonStockPurchased
Namespace Prefix: | nktr_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | instant

X
- Definition Upfront and milestone payments received from license agreements. + References No definition available. + Details
Name: | nktr_UpfrontAndMilestonePaymentsReceivedFromLicenseAgreements
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Upfront and milestone payments received under license agreement. + References No definition available. + Details
Name: | nktr_UpfrontAndMilestonePaymentsReceivedUnderLicenseAgreement
Namespace Prefix: | nktr_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 13.A.3) -URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 13.A.4(a).Q1) -URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780 + Details
Name: | us-gaap_DeferredRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_DeferredRevenueArrangementLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 13.A.3(b).Q1(c)) -URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 8 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6935-107765 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB TOPIC 13.A.4(a).Q1) -URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 13.A.3) -URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 13.A.3(b).Q2) -URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 13.A.3(b)) -URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 13.A.3(c).Q3) -URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780 + Details
Name: | us-gaap_DeferredRevenueCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section 45 -Paragraph 8 -Subparagraph (b) -URI http://asc.fasb.org/extlink&oid=82887183&loc=d3e6935-107765 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 13.A.3(c).Q3) -URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 13.A.4(a).Q1) -URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 13.A.3(b)) -URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 13.A.3(b).Q1(c)) -URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 13.A.3) -URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 13.A.3(b).Q2) -URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780 + Details
Name: | us-gaap_DeferredRevenueNoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Revenue from multiple-deliverable arrangements that include licensing fees and maintenance revenue. Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Maintenance revenue is derived from maintenance services provided under contracts or arrangements with clients. Services may include the maintenance of software, plant and equipment, and facilities. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1(d),(e)) -URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688 + Details
Name: | us-gaap_LicenseAndMaintenanceRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of consideration recognized during the period for the milestone or milestones. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 605 -SubTopic 28 -Section 50 -Paragraph 2 -Subparagraph (e) -URI http://asc.fasb.org/extlink&oid=68058744&loc=SL6892177-166501 + Details
Name: | us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Per share or per unit amount of equity securities issued. + References No definition available. + Details
Name: | us-gaap_SharesIssuedPricePerShare
Namespace Prefix: | us-gaap_
Data Type: | num:perShareItemType
Balance Type: | na
Period Type: | instant

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nktr_AstraZenecaAgreementWithKirinMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConsolidatedEntitiesAxis=us-gaap_ParentCompanyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nktr_NektarThreeFiveEightMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ProductOrServiceAxis=nktr_NektarTwoOneFourMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nktr_BMSCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=nktr_OpdivoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=nktr_OpdivoAndYervoyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=nktr_BaxaltaIncorporatedOrShirePLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nktr_HemophiliaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementGeographicalAxis=us-gaap_EuropeanUnionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=nktr_BristolMyersSquibbCompanyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsidiarySaleOfStockAxis=nktr_SharePurchaseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nktr_ClinicalTrialAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=nktr_EliLillyAndCompanyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DeferredRevenueArrangementTypeAxis=nktr_LicenseArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DeferredRevenueArrangementTypeAxis=nktr_PhaseOneClinicalDevelopmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DeferredRevenueArrangementTypeAxis=nktr_DrugProductDevelopmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RangeAxis=us-gaap_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=nktr_EliLillyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=nktr_AmgenIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=nktr_AstraZenecaAbMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nktr_MOVANTIKAndMOVANTIKFixedDoseCombinationProgramMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_DeferredRevenueArrangementTypeAxis=us-gaap_UpFrontPaymentArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=nktr_MOVANTIKFixedDoseCombinationProgramMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=nktr_OtherPartnerMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |